Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 48 for “"K-ras"”.
-
Investigating K-Ras inhibition by α-helical peptides
Mutations in the KRAS gene are common drivers of human cancer and inhibition of KRas is a key goal in drug discovery. Recently, the development of covalent K-Ras(G12C) inhibitors has presented a breakthrough in the field and challenged the belief that K-Ras was "undruggable". Despite this, there …
-
Mechanism of mitochondrial respiratory dysfunction by oncogenic K-Ras
… oncogene driving transformation, oncogenic K-RasV12 was adopted to transform cultured fibroblast. When cultured Rat-2 fibroblast cells were infected with a retrovirus harboring constitutively active K-RasV12, the expressions of both respiratory and non-respiratory proteins were decreased. Such …
-
Increased Geranylgeranylated K-Ras Contributes to Antineoplastic Effects of Farnesyltransferase Inhibitors.
<p>The Ras family of small GTPases (N-, H-, and K-Ras) is a group of important signaling mediators. Ras is frequently activated in some cancers, while others maintain low level activity to achieve optimal cell growth. In cells with endogenously low levels of active Ras, increasing Ras signaling …
-
Functional analysis of K-ras in the mouse by gene targeting
Thesis (Ph. D.)--Massachusetts Institute of Technology, Dept. of Biology, 1996.
-
Targeting immunosuppression in the tumor microenvironment and protein-based antagonism of oncogenic K-Ras
… In the field of targeted therapy, mutant K-Ras continues to be the holy grail of oncogenic targets, but remains undruggable due to its high affinity for activating nucleotide GTP and a lack of welldefined drug-binding pockets. We engineered a protein binder RI 1.1.6 that binds mutant K-Ras …
-
Tissue-specific interactions between oncogenic K-ras and the p19A̳r̳f̳_p53 pathway determine susceptibility to transformation
… is largely unknown. The ability of oncogenic Ras to induce the tumor suppressive p1 9 Arf-p5.3 pathway and cause irreversible cell cycle arrest typifies this phenomenon. Using this-well established interaction as model, we investigated the cell-type specificity of oncogene-induced tumor …
-
HeLa에서 K-ras 과발현시 활성산소 발생에 의한 핵모양의 이상의 발생과 이중핵/다핵 세포 증가 현상 연구
… well known characteristics of cancer cells. K-Ras is frequently mutated in many cancers. One of the oncogene mutants, K-RasV12 has been reported to generate reactive oxygen species (ROS). We recently observed that increased ROS generates polyploidy and abnormal nuclear shape in HeLa cells. We …
-
Conformational Dynamics of K-Ras and H-Ras Proteins: Is There Functional Specificity At The Catalytic Domain?
<p>Ras proteins serve as crucial signaling modulators in cell proliferation through their ability to hydrolyze GTP and exist in a GTP “on” state and GTP “off” state. There are three different human Ras isoforms: H-ras, N-ras and K-ras (4A and 4B). Although their sequence identity is very high at …
-
Acceleration of The Panin Development In Mice Expressing Oncogenic K-Ras Due to A High Fat Diet
… involved are unclear. Oncogenic mutation of K-Ras is found early and is universal in pancreatic cancer. Extensive evidence indicates oncogenic K-Ras is not entirely active and it requires a triggering event to surpass the activity of Ras beyond the threshold necessary for a Ras-inflammation …
-
Exploring the Role of IL-1β/IL-1R in the Pathogenesis of K-ras Mutant Lung Cancer
… adenocarcinoma with driver mutations in the K-ras oncogene (KM-LUAD). KM-LUAD progression partly occurs through activation of the NF-κB pathway initiating an inflammatory response and creating a pro-tumor microenvironment. Notably, the pro-inflammatory cytokine IL-1β a potent activator and …
-
STAT3, NF-κB, and Estrogen Receptor Beta: The Balance of Inflammation in K-ras Mutant Lung Adenocarcinoma
<p>K-ras mutant lung adenocarcinoma (KM-LUAD) is a difficult-to-treat cancer subtype in which chronic inflammation pervades the tumor immune microenvironment (TIME). Pro-inflammatory pathways dampen the response to treatments, including immune checkpoint inhibitors, necessitating therapies that …
-
Dissecting the Relationship between Mucin 5AC and the Lung/Gut Microbiome in the Pathogenesis of K-ras Mutant Lung Cancer
… deaths worldwide. In LUAD patients, KRAS mutations are the most common oncogenic driver alteration. Given KRAS is upstream to many signaling pathways involved in cell survival and cytokine production, interventions against KRAS-mutant lung cancers are prone to develop acquired …
-
Quantitative analysis of K-ras mutation in urine as an indicator of disease status in patients with stage II or higher colorectal cancer
Thesis (M.S.)--Michigan State University. Department of Clinical Laboratory Sciences, 2008
-
Direct Effects of Metformin On Pi3K and Ras Signaling In Endometrial Cancer
… effect on cell proliferation, PI3K and Ras-MAPK signaling, and apoptosis. A xenograft mouse model was also used to evaluate the effects of metformin treatment on <em>in vivo</em> tumor growth. These preliminary studies demonstrated that K-Ras mutant cell lines exhibited a decreased …
-
The effect of RAN inhibition on human colorectal cancer cells (CRC)
… metastasise to the liver through the effect of K-Ras and Pten mutation (Mt.) (Abbas et al. 2020). This study aimed to assess the hypothesis that the Ran inhibitor mebendazole MBZ reduces cell invasion and metastasis of CRC. I have investigated MBZ effect on the CRC isogenic human cell lines with …
-
Aberrant Ras/MAPK signaling in skeletal development
… (NS), that are caused by aberrant germline Ras/MAPK signaling. One hallmark of these developmental syndromes is a defect in the skeletal development of the patients. However, the in vivo role of MAPK signaling during bone development is still controversial, with some studies supporting a …
-
Loss of TBK1 Kinase Function Improves Disease Outcome in Pancreatic Cancer and Metabolic Syndrome
… disease progression. Activating mutations in KRAS are present in 90% of human PDA cases; yet direct pharmacological inhibition of K-RAS remains a challenge, indicating a need for effective therapies. Higher levels of TBK1 mRNA, a critical downstream mediator of oncogenic K-RAS in lung cancer, …
-
Development and Characterization of Novel Ras Inhibitors
<p>Ras genes are mutated in 15% of human cancers. Ras GTPases operate as molecular switches regulating cellular processes including proliferation, differentiation, and apoptosis. The three main isoforms of Ras – H-Ras, K-Ras, and N-Ras – inhabit distinct nanodomains of the plasma membrane and …
-
The Mechanism of Tumorigenesis In The Immortalized Human Pancreatic Cell Lines: Cell Culture Models of Human Pancreatic Cancer
… identified in PDAC include activation of K-ras (90%) and Her2 (70%), loss of p16 (95%) and p14 (40%), inactivation p53 (50-75%) and Smad4 (55%). However, the role of these signature gene alterations in PDAC is still not well understood, especially, how these genetic lesions individually or …
Page 1 of 3